Govorestat Faces FDA Rejection, Leaving Galactosemia Patients Without Hope The FDA's denial of Govorestat, the sole potential treatment for Classic Galactosemia, leaves patients and families in despair. Advocacy continues for their reconsideration.

Govorestat Faces FDA Rejection, Leaving Galactosemia Patients Without Hope #USA #Albany #Galactosemia_Foundation #Govorestat #Classic_Galactosemia